

Catalog # 10-4782 Crenolanib

CAS# 670220-88-9

1-[2-[5-[(3-Methyloxetan-3-yl)methoxy]benzimidazole-1-yl]quinoline-8-yl]piperidin-4-amine; CP-868,596 Lot # FBS2030

Crenolanib is a potent inhibitor of PDGFR (K_d for α = 2.1 nM; β = 3.2 nM) and FLT3 (K_d = 0.74 nM). Crenolanib is a type I inhibitor binding only to the active kinase conformation. It showed potent activity against imatinib-resistant PDGFR α mutations D842I, D842V, D842Y, DI842-843M, and deletion I843² as well as FLT3/ITD and FLT3/D835 mutants³. Crenolanib acted synergistically with FLT3-CAR T-cells in a FLT3-ITD+ AML murine xenograft model.⁴

- 1) Lewis et al. (2009) Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers; J. Clin. Oncol. **27** 5262
- 2) Smith et al. (2014) Crenolanib is a selective type I pan-FLT3 inhibitor; Proc. Natl. Acad. Sci. USA 111 5319
- 3) Heinrich et al. (2012) Crenolanib Inhibits Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors; Clin. Cancer Res. **18** 4375
- 4) Jetani et al. (2018) CAR T-cells targeting FLT3 have potent activity against FLT-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib; Leukemia **32** 1168

PHYSICAL DATA

Molecular Weight: 443.55

Molecular Formula: $C_{26}H_{29}N_5O_2$ Purity: >97% by HPLC

NMR: (Conforms)

Solubility: DMSO (15 mg/mL); ethanol (10 mg/mL)

Physical Description: White solid

Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO or ethanol may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462 <u>www.focusbiomolecules.com</u>